article thumbnail

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

The Pharma Data

are living with spasticity across a variety of neurologic conditions — BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity. Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. million adults in the U.S.

Botox 52
article thumbnail

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

The Pharma Data

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Want to Join a Women’s Health Research Study? This May be Your Chance to Contribute to UUI Solutions

Trialfacts

The goal of this study is to compare two treatments: Mirabegron or Vibegron (oral medications) versus Botox A® (an injected medication). All clinic visits for both Beta-3 Agonist medication and BOTOX® go through normal clinical care and health insurance. UUI can have a negative effect on women’s quality of life. Read on to learn more!

Botox 52
article thumbnail

AbbVie to Highlight Its Leadership in Movement Disorders at the.

The Pharma Data

” Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA ® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX ® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.

Botox 52
article thumbnail

US FDA approves expanded indication for AbbVie’s oral migraine therapy

Pharmaceutical Technology

In a separate development, AbbVie’s Rinvoq (upadacitinib, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) received the European Commission’s approval to treat moderately to severely active Crohn’s disease in adult patients. The 60mg dose is indicated for chronic migraine patients.

article thumbnail

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

The Pharma Data

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. . IMPORTANT SAFETY INFORMATION.

Botox 52
article thumbnail

Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting

The Pharma Data

vice president, neuroscience development, AbbVie. About Atogepant Atogepant is an investigational orally administered, CGRP receptor antagonist (gepant) specifically developed for the preventive treatment of migraine. About BOTOX ®. BOTOX ® (onabotulinumtoxinA) Important Information. Indications.

Botox 52